Mitochondrial common deletion, a potential biomarker for cancer occurrence, is selected against in cancer background: a meta-analysis of 38 studies.
Mitochondrial common deletion, a potential biomarker for cancer occurrence, is selected against in cancer background: a meta-analysis of 38 studies.
复制标题
线粒体常见缺失是癌症发生的潜在生物标志物，在癌症背景下被选择：对 38 项研究的荟萃分析
DOI：
10.1371/journal.pone.0067953
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Bai Y
中科院分区：
文献类型：
--
作者：
Nie H;Shu H;Vartak R;Milstein AC;Mo Y;Hu X;Fang H;Shen L;Ding Z;Lu J;Bai Y
线粒体功能障碍一直被认为在肿瘤发生中起主要作用。线粒体DNA（mitochondrialDNA，mtDNA）突变，尤其是mtDNA 4, 977 bp缺失在多种癌症患者中均有发现。为了了解不同类型癌症中mtDNA 4，977 bp缺失的情况，我们对33篇文献进行了荟萃分析，其中包括1613例癌症病例，1516例邻近正常人和638例健康对照。将所有研究结果汇总后发现，在不同类型的癌症中，癌组织的mtDNA 4,977 bp缺失频率低于癌旁组织（OR = 0.43，95%CI = 0.20-0.92，异质性检验P=0.03，I2= 91.5%）。 按癌型分层分析，乳腺癌癌组织中的缺失频率甚至低于癌旁正常组织（OR = 0.19，95% CI = 0.06-0.61，P = 0.005，异质性检验，I2 = 82.7%）。 有趣的是，这一观察结果在样本量较大的分层研究中变得更加显著（OR = 0.70，95%CI = 0.58-0.86，异质性检验P=0.0005，I2= 95.1%）。 与正常对照组相比，癌旁非癌组织（OR = 3.02，95%CI = 2.13-4.28，P<0.00001）和癌组织（OR = 1.36，95%CI = 1.04-1.77，P = 0.02，I2 = 83.5%）的缺失频率均增高。 这项荟萃分析表明，mtDNA 4，977 bp缺失经常在癌组织中发现，因此有可能成为组织中癌症发生的生物标志物，但同时在各种类型的癌组织中被选择。更大和更好的设计研究仍然需要证实这些发现。
Mitochondrial dysfunction has been long proposed to play a major role in tumorigenesis. Mitochondrial DNA (mtDNA) mutations, especially the mtDNA 4,977 bp deletion has been found in patients of various types of cancer. In order to comprehend the mtDNA 4,977 bp deletion status in various cancer types, we performed a meta-analysis composed of 33 publications, in which a total of 1613 cancer cases, 1516 adjacent normals and 638 healthy controls were included. When all studies were pooled, we found that cancerous tissue carried a lower mtDNA 4,977 bp deletion frequency than adjacent non-cancerous tissue (OR = 0.43, 95% CI = 0.20–0.92, P = 0.03 for heterogeneity test, I2 = 91.5%) among various types of cancer. In the stratified analysis by cancer type the deletion frequency was even lower in tumor tissue than in adjacent normal tissue of breast cancer (OR = 0.19, 95% CI = 0.06–0.61, P = 0.005 for heterogeneity test, I2 = 82.7%). Interestingly, this observation became more significant in the stratified studies with larger sample sizes (OR = 0.70, 95% CI = 0.58–0.86, P = 0.0005 for heterogeneity test, I2 = 95.1%). Furthermore, when compared with the normal tissue from the matched healthy controls, increased deletion frequencies were observed in both adjacent non-cancerous tissue (OR = 3.02, 95% CI = 2.13–4.28, P<0.00001 for heterogeneity test, I2 = 53.7%), and cancerous tissue (OR = 1.36, 95% CI = 1.04–1.77, P = 0.02 for heterogeneity test, I2 = 83.5%). This meta-analysis suggests that the mtDNA 4,977 bp deletion is often found in cancerous tissue and thus has the potential to be a biomarker for cancer occurrence in the tissue, but at the same time being selected against in various types of carcinoma tissues. Larger and better-designed studies are still warranted to confirm these findings.
登录
查看更多内容
影响因子：
11.2
作者：
HOLT, IJ;HARDING, AE;MORGANHUGHES, JA
通讯作者：
MORGANHUGHES, JA
影响因子：
14.9
作者：
CORTOPASSI, GA;ARNHEIM, N
通讯作者：
ARNHEIM, N
影响因子：
4.2
作者：
Futyma, Konrad;Putowski, Lechoslaw;Semczuk, Andrzej
通讯作者：
Semczuk, Andrzej
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
3.3
作者：
Berneburg, M;Gattermann, N;Krutmann, J
通讯作者：
Krutmann, J